4d Pharma's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott its phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients in hospital with COVID-19 is now open to enrolment. Dosing of the first patients should begin shortly and Peyton says that as MRx-4DP0004 is a live biotherapeutic it's expected to show a favourable safety profile.
4d Pharma's Duncan Peyton updates as enrolment begins for Phase II COVID-19 study
Quick facts: 4D pharma plc
Price: 160 GBX
Market Cap: £210.23 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE